Edition:
United States

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

33.17USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$33.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
142,580
52-wk High
$41.24
52-wk Low
$16.71

Select another date:

Tue, Jan 30 2018

BRIEF-La Jolla Pharmaceutical Says Established Wholesale Acquisition Cost of Single-Dose Vial Of Giapreza At $1,500/ Vial

* LA JOLLA PHARMACEUTICAL CO - ESTABLISHED WHOLESALE ACQUISITION COST OF $1,500 PER VIAL FOR A 1 ML, SINGLE-DOSE, 2.5 MG/ML VIAL OF GIAPREZA Source text: (http://bit.ly/2nm3hfv) Further company coverage:

BRIEF-Broadfin Capital Reports 5 Percent Passive Stake In La Jolla Pharmaceutical - SEC Filing‍​

* BROADFIN CAPITAL LLC REPORTS 5 PERCENT PASSIVE STAKE IN LA JOLLA PHARMACEUTICAL CO AS OF JAN 9 - SEC FILING‍​ Source text: (http://bit.ly/2D4NbRm) Further company coverage:

BRIEF-La Jolla Pharmaceutical Says Cash Resources Are Expected To Fund Co Into Second Half Of 2018

* LA JOLLA PHARMACEUTICAL SAYS CASH RESOURCES ARE EXPECTED TO FUND CO INTO SECOND HALF OF 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2BTfmOK) Further company coverage:

FDA approves La Jolla's low blood pressure drug

La Jolla Pharmaceutical said on Thursday the U.S. Food and Drug Administration had approved its drug, Giapreza, to treat dangerously low blood pressure.

FDA approves La Jolla's low blood pressure drug

Dec 21 La Jolla Pharmaceutical said on Thursday the U.S. Food and Drug Administration had approved its drug, Giapreza, to treat dangerously low blood pressure.

BRIEF-La Jolla Says FDA Approved Drug To Treat Critically Low Blood Pressure

* U.S. FOOD AND DRUG ADMINISTRATION SAYS APPROVED GIAPREZA (ANGIOTENSIN II) TO TREAT DANGEROUSLY LOW BLOOD PRESSURE

BRIEF-La Jolla Pharmaceutical Initiates Multicenter, Randomized, Phase 2 Clinical Study Of LJPC‑401

* INITIATION OF MULTICENTER, RANDOMIZED, PHASE 2 CLINICAL STUDY OF LJPC-401 IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS Source text for Eikon: Further company coverage:

BRIEF-La Jolla Pharma files for mixed shelf of up to $150 mln ‍​

* Files for mixed shelf of up to $150 million - SEC filing‍​ Source text : [http://bit.ly/2zK9cPg] Further company coverage:

BRIEF-La Jolla reports Q3 loss $1.19/shr

* La Jolla Pharmaceutical Company announces financial results for the three and nine months ended September 30, 2017 and recent corporate progress

BRIEF-Prudential Financial reports 10.1 pct passive stake ​in La Jolla Pharmaceutical

* Prudential Financial Inc reports 10.1 percent passive stake ​in La Jolla Pharmaceutical Co as of Sept 30 - sec filing ‍ Source text : [http://bit.ly/2g07Ckv] Further company coverage:

Select another date: